STOCK TITAN
  1. Home
  2. Sec-filings
  3. LYEL
  4. [Form 4] Lyell Immunopharma, Inc. Insider Trading Activity

Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lyell Immunopharma director Mark Bachleda received a grant of stock options for 9,250 shares of common stock. These options give him the right to buy 9,250 shares at an exercise price of $13.22 per share and expire on June 9, 2036.

The award is compensation-related and was not an open-market purchase. According to the vesting terms, all 9,250 option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of that date, provided he continues serving as a director through the vesting date.

Positive

  • None.

Negative

  • None.
Insider Bachleda Mark
Role null
Type Security Shares Price Value
Grant/Award Option (right to buy) 9,250 $0.00 --
Holdings After Transaction: Option (right to buy) — 9,250 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 9,250 shares Options to buy common stock granted to director
Exercise price $13.22/share Strike price for 9,250 option shares
Shares after transaction 9,250 options Total derivative holdings following the grant
Expiration date June 9, 2036 Option expiration
Vesting reference date June 10, 2026 Used to determine vesting at meeting or first anniversary
Option (right to buy) financial
"security_title: "Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "13.2200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"subject to the Reporting Person providing continuous service through such date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bachleda Mark
(Last)(First)(Middle)
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY, SUITE 101
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy)$13.2206/10/2026A9,250 (1)06/09/2036Common Stock9,250$09,250D
Explanation of Responses:
1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
/s/ Mark Meltz, Attorney-in-Fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Lyell Immunopharma (LYEL) director Mark Bachleda report on this Form 4?

Mark Bachleda reported receiving an option grant for 9,250 shares of Lyell Immunopharma common stock. The options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

How many Lyell Immunopharma (LYEL) options did Mark Bachleda receive and at what price?

He received options covering 9,250 shares of common stock at an exercise price of $13.22 per share. This means he can buy up to 9,250 shares at $13.22 regardless of future market price, once the options vest.

When do Mark Bachleda’s Lyell Immunopharma (LYEL) options vest?

All 9,250 option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of that date. Vesting requires that he provide continuous service as a director through the applicable vesting date.

When do the options granted to Lyell Immunopharma (LYEL) director Mark Bachleda expire?

The options expire on June 9, 2036. After that date, any unexercised options become worthless, so they must be exercised, if at all, before the expiration date while still valid and vested.

Is this Lyell Immunopharma (LYEL) Form 4 an open-market purchase or a compensation grant?

This Form 4 reports a compensation-related grant, coded as a grant, award, or other acquisition. The transaction price per share is $0.00, indicating an option award rather than an open-market purchase of Lyell Immunopharma stock.